Yuan Z, et al. - In this retrospective review of patients with uterine (n=32) and cervical adenosarcoma (n=21), researchers focused on the features and oncologic outcomes of these cases. Participants were observed over a median of 37.5 months (range, 1-153 months). The prognosis was better in cases with cervical adenosarcoma vs cases with uterine adenosarcoma; disease progression rate was significantly higher in patients with uterine adenosarcoma (28.1%) vs cervical adenosarcoma (4.8%). A protective factor was the presence of a tumor stalk; heterologous elements and lymphovascular space invasion were identified as risk factors for progression. It would be mandatory to perform a robust evaluation in uterine adenosarcoma cases if fertility-sparing surgery (FSS) was administered. No strong conclusions could be made about FSS due to small sample size.